SABCS 2023 to Feature a Session on Lobular Breast Cancer

The San Antonio Breast Cancer Symposium (SABCS) is an annual event hosting thousands of clinicians and scientists and is the largest scientific gathering on breast cancer research. Registration is now open for this year’s event, which will take place from December 5 to December 9 in San Antonio, Texas.

The Lobular Breast Cancer Alliance (LBCA) is thrilled that this year’s SABCS will include a session on invasive lobular carcinoma (ILC), also known as lobular breast cancer. LBCA is proud to be a sponsor of this portion of the symposium. The session will be moderated by LBCA Scientific Advisory Board (SAB) Founding Chair Steffi Oesterreich, PhD, and the patient advocate panelist will be Siobhán Freeney from Lobular Ireland and the European Lobular Breast Cancer Consortium (ELBCC), with which LBCA is affiliated.

Topics include:

  • Biological peculiarities of ILC presented by ELBCC’s Christine Desmedt, PhD
  • Diagnosis, prognosis, and surveillance: What is different? presented by Tari A. King, MD, FACS
  • Innovative approaches for lobular breast cancer presented by LBCA SAB member Jason Mouabbi, MD

Held in conjunction with SABCS is the Alamo Advocate Program. The program provides patient advocates in attendance a chance to interact with leading medical experts during Hot Topics Mentor Sessions. It also includes panels and interviews. LBCA encourages any patient advocate attendees at SABCS to also attend the Alamo program. Registration opens August 1 for the program.

Of note: The Alamo Breast Cancer Foundation is sponsoring select patient advocates to attend SABCS and take part in Alamo’s special patient advocate program via its scholarship program. The application process is now open. Learn more by visiting the Alamo Breast Cancer Foundation website.

Stay tuned for more information to come about an important road race in San Antonio in December that can benefit LBCA and about other LBCA-sponsored events during SABCS 2023.

Share this article:
Scroll to Top

Join Us

Subscribe for the Latest News & Updates​

  • This field is for validation purposes and should be left unchanged.